样式: 排序: IF: - GO 导出 标记为已读
-
The Role of Genetics in Advancing Cardiometabolic Drug Development Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2024-03-07 Roukoz Abou-Karam, Fangzhou Cheng, Shoshana Gady, Akl C. Fahed
-
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 American Heart Association Scientific Sessions Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2024-03-05 Melody Hermel, Andrew Chiou, Abdul Mannan Khan Minhas, Maha Inam, Carly E. Waldman, Eventine Youngblood, Sandeep Mehta, Leandro Slipczuk, Sana Sheikh, Chelsea Meloche, Adeel Khoja, Salim S. Virani
Purpose of Review Focused review highlighting ten select studies presented at the 2023 American Heart Association (AHA) Scientific Sessions. Recent Findings Included studies assessed semaglutide and cardiovascular outcomes in overweight or obese patients without diabetes (SELECT); dapagliflozin in patients with acute myocardial infarction without diabetes (DAPA-MI); effects of dietary sodium on systolic
-
European Lipid Guidelines and Cardiovascular Risk Estimation: Current Status and Future Challenges Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2024-03-02 Angela Pirillo, Lale Tokgözoğlu, Alberico L. Catapano
-
Implications of Bias in Artificial Intelligence: Considerations for Cardiovascular Imaging Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2024-02-16 Marly van Assen, Ashley Beecy, Gabrielle Gershon, Janice Newsome, Hari Trivedi, Judy Gichoya
-
Novel Therapies for Lipoprotein(a): Update in Cardiovascular Risk Estimation and Treatment Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2024-02-05 Anders Berg Wulff, Børge G. Nordestgaard, Anne Langsted
-
How Will Our Practice Change After the CLEAR Outcomes Trial? Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2024-01-31 Timothy Abrahams, Adam J. Nelson, Stephen J. Nicholls
-
Increased Cardiovascular Risk in Young Patients with CKD and the Role of Lipid-Lowering Therapy Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2024-01-30
Abstract Purpose of Review Chronic kidney disease (CKD) is associated with a significantly increased risk of cardiovascular disease (CVD). This review summarizes known risk factors, pathophysiological mechanisms, and current therapeutic possibilities, focusing on lipid-lowering therapy in CKD. Recent Findings Novel data on lipid-lowering therapy in CKD mainly stem from clinical trials and clinical
-
Lipoprotein(a): from Causality to Treatment Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2024-01-22 Florian Kronenberg
-
Psychological Health and Ischemic Heart Disease in Women: A Review of Current Evidence and Clinical Considerations across the Healthspan Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2024-01-19 Allison E. Gaffey, Erica S. Spatz
-
Targeting the Gut Microbiome to Treat Cardiometabolic Disease Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2024-01-05 Panagiotis Theofilis, Panayotis K. Vlachakis, Evangelos Oikonomou, Konstantinos Tsioufis, Dimitris Tousoulis
-
Whether and Why Do We Need a Vaccine Against Atherosclerosis? Can We Expect It Anytime Soon? Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2024-01-02 Stanisław Surma, Amirhossein Sahebkar, Maciej Banach
-
Risk Stratification and Treatment of Obesity for Primary and Secondary Prevention of Cardiovascular Disease Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2023-12-30 John W. Ostrominski, Tiffany M. Powell-Wiley
-
Body Fat Depletion: the Yin Paradigm for Treating Type 2 Diabetes Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2023-12-27 Jingjing Zhu, John P. H. Wilding
-
Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2023-12-22 John J. P. Kastelein, Andrew Hsieh, Mary R. Dicklin, Marc Ditmarsch, Michael H. Davidson
-
How to Handle Elevated Triglycerides: Life after PROMINENT Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2023-12-20
Abstract Purpose of Review Hypertriglyceridaemia (HTG) is a common condition characterised by elevated levels of plasma triglycerides (TG), which are transported in the blood mainly by TG-rich lipoproteins (TRL). Elevated TG levels (150–400 mg/dL) are associated with increased cardiovascular risk. Severe HTG (>880 mg/dL) is associated with a risk of acute pancreatitis only. Randomised clinical trials
-
Eliminating Health Disparities in Atrial Fibrillation, Heart Failure, and Dyslipidemia: A Path Toward Achieving Pharmacoequity Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2023-12-18 Krunal Amin, Garrett Bethel, Larry R. Jackson, Utibe R. Essien, Caroline E. Sloan
-
Machine Learning in Invasive and Noninvasive Coronary Angiography Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2023-12-14 Ozan Unlu, Akl C. Fahed
-
Inhibition of Angiopoietin-Like Protein 3 or 3/8 Complex and ApoC-III in Severe Hypertriglyceridemia Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2023-12-14 Miriam Larouche, Etienne Khoury, Diane Brisson, Daniel Gaudet
-
Sex Differences in Cardiac Transplantation Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2023-12-07 Alice Chung, Heidi Hartman, Ersilia M. DeFilippis
-
Should Familial Hypercholesterolaemia Be Included in the UK Newborn Whole Genome Sequencing Programme? Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2023-12-07 Steve E Humphries, Uma Ramaswami, Neil Hopper
-
HDL as a Treatment Target: Should We Abandon This Idea? Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2023-12-05 Floran Begue, Marie Laurine Apalama, Gilles Lambert, Olivier Meilhac
-
Polysocial Risk Scores: Implications for Cardiovascular Disease Risk Assessment and Management Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2023-12-04 Zulqarnain Javed, Harun Kundi, Ryan Chang, Anoop Titus, Hassaan Arshad
-
Heart Failure Treatment in 2023: Is There a Place for Lipid Lowering Therapy? Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2023-12-04 Hana Poloczková, Jan Krejčí
Purpose of Review An evidence for lipid lowering therapy in heart failure is briefly summarized in this review. Recent Findings Heart failure therapy is based on recent guidelines for diagnosis and treatment of acute and chronic heart failure. The question of the importance of hypolipidemic treatment in heart failure remains insufficiently answered. We still rely only on results of two randomized controlled
-
Polycystic Ovarian Syndrome: a Risk Factor for Cardiovascular Disease Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2023-12-04 Yulith Roca Alvarez, Madison Pico, Namrita Ashokprabhu, Kareem Abou-Amro, Samantha Bailey, Elizabeth Pung, Evan Oberholster, Odayme Quesada
-
Emerging Preventive Strategies in Chronic Kidney Disease: Recent Evidence and Gaps in Knowledge Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2023-12-01 Nishigandha Pradhan, Mirela Dobre
-
Natural Sirtuin1 Activators and Atherosclerosis: an Overview Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2023-12-01 Karolina Łanoszka, Nimasha Vlčková
Purpose of Review The purpose of this review is to summarize the most recent findings investigating the impact of several natural sirtuin (SIRT) activators, particularly SIRT1, on atherosclerosis. Recent Findings Sirtuins that belong to a family of class III histone deacetylases are believed to be novel therapeutic targets to treat age-related and chronic diseases. SIRT expression is regulated by small
-
Machine Learning in Cardiovascular Risk Prediction and Precision Preventive Approaches Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2023-11-27 Nitesh Gautam, Joshua Mueller, Omar Alqaisi, Tanmay Gandhi, Abdallah Malkawi, Tushar Tarun, Hani J. Alturkmani, Muhammed Ali Zulqarnain, Gianluca Pontone, Subhi J. Al’Aref
-
Caregiver Influences on Eating Behaviors in Children: An Opportunity for Preventing Obesity Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2023-11-30 Lorraine M. Schratz, Olivia Larkin, Nilse Dos Santos, Christine Martin
-
Lipid Lowering Drugs in Acute Coronary Syndromes (ACS) Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2023-11-28 Natalie Arnold, Wolfgang Koenig
-
Gene Regulatory Networks in Coronary Artery Disease Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2023-11-27 Jenny Cheng, Michael Cheng, Aldons J. Lusis, Xia Yang
-
Obesity and Dyslipidemia Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2023-11-18 Barbora Nussbaumerova, Hana Rosolova
Purpose of Review This article sumarizes pathopysiological consequencies between obesity and dyslipidemia and aims to bring some practical approach. Recent Findings Dyslipidemia is often present in individuals with obesity and simultaneusly, many obese individuals have lipid metabolism disorders. Especially the abdominal obesity increases the cardiometabolic risk because of the presence of atherogenic
-
Rap1 in the Context of PCSK9, Atherosclerosis, and Diabetes Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2023-11-18 Heena Agarwal, Brea Tinsley, Amesh K. Sarecha, Lale Ozcan
Purpose of Review The focus of this article is to highlight the importance of the small GTPase, Ras-associated protein 1 (Rap1), in proprotein convertase subtilisin/kexin type 9 (PCSK9) regulation and atherosclerosis and type 2 diabetes etiology and discuss the potential therapeutic implications of targeting Rap1 in these disease areas. Review Findings Cardiometabolic disease characterized by obesity
-
Coronary and Extra-coronary Subclinical Atherosclerosis to Guide Lipid-Lowering Therapy Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2023-11-16 Jelani K. Grant, Carl E. Orringer
-
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 European Society of Cardiology Congress Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2023-11-17 Kartik Gupta, Colin Hinkamp, Tyler Andrews, Chelsea Meloche, Abdul Mannan Khan Minhas, Leandro Slipczuk, Elizabeth Vaughan, Fatima Zohra Habib, Sana Sheikh, Dinesh Kalra, Salim S. Virani
Purpose of Review To summarize selected late-breaking science on cardiovascular (CV) disease prevention presented at the 2023 European Society of Cardiology (ESC) congress. Recent Findings The NATURE-PARADOX was a naturally randomized trial that used genetic data from the UK Biobank registry to create “cumulative exposure to low-density lipoprotein-cholesterol (LDL-C)” biomarker and evaluate its association
-
Stratification in Heterozygous Familial Hypercholesterolemia: Imaging, Biomarkers, and Genetic Testing Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2023-11-03 Pablo Corral, Carlos A. Aguilar Salinas, María Gabriela Matta, Valeria Zago, Laura Schreier
-
The Role of Lipid-Lowering Therapy in Post-Stroke Patients: Update and Recommendations Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2023-10-26 E. Avenatti, J. A. Carrasco-Avila, B. Heidari, K. Hagan, M. Taha, K. Nasir
Purpose of Review Stroke is the second leading cause of death and disability-adjusted life years worldwide, and the global lifetime risk of stroke is rising. Moreover, patients with a prior stroke are at high risk of recurrent events. We aimed at reviewing the evidence supporting aggressive secondary prevention strategies for lipid-lowering treatment in this population. Recent Findings Statins are
-
Predictive Modeling and Structure Analysis of Genetic Variants in Familial Hypercholesterolemia: Implications for Diagnosis and Protein Interaction Studies Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2023-10-17 Asier Larrea-Sebal, Shifa Jebari-Benslaiman, Unai Galicia-Garcia, Ane San Jose-Urteaga, Kepa B. Uribe, Asier Benito-Vicente, César Martín
-
Rhabdomyolysis or Severe Acute Hepatitis Associated with the Use of Red Yeast Rice Extracts: an Update from the Adverse Event Reporting Systems Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2023-10-13 Maciej Banach, Giuseppe Danilo Norata
Purpose of Review Elevated plasma levels of low-density lipoprotein cholesterol (LDL-C) are a major risk factor for atherosclerotic cardiovascular disease (ASCVD), and lowering LDL-C reduces the risk of cardiovascular adverse events. Among natural approaches known for their lipid-lowering properties, red yeast rice (RYR) has a cholesterol-lowering effect due to the presence of bioactive components
-
Mechanisms Behind NAFLD: a System Genetics Perspective Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2023-10-09 Shirin Pourteymour, Christian A. Drevon, Knut Tomas Dalen, Frode A. Norheim
-
Percutaneous Coronary Interventions in Women Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2023-10-10 Golsa Joodi, Sristi Palimar, Marcella Calfon Press
Purposeof Review Cardiovascular disease is the leading cause of morbidity and mortality among women globally. Numerous studies show ongoing disparities in diagnosis, management, and outcomes of ischemic heart disease in women compared to men. We aim to review the factors contributing to sex-based differential outcomes of percutaneous coronary interventions in women. Recent Findings Hormonal influence
-
Sex Differences in Familial Hypercholesterolemia Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2023-10-10 Marianne Klevmoen, Janneke W.C.M. Mulder, Jeanine E. Roeters van Lennep, Kirsten B. Holven
-
Statin Use and Coronary Artery Calcification: a Systematic Review and Meta-analysis of Observational Studies and Randomized Controlled Trials Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2023-10-05 Mitra Nekouei Shahraki, Soroush Mohammadi Jouabadi, Daniel Bos, Bruno H. Stricker, Fariba Ahmadizar
Purpose of Review This review aimed to determine the association between statin use and coronary artery calcification (CAC), as detected by computed tomography in the general population, in previously published observational studies (OSs) and randomized controlled trials (RCTs). Recent Findings A systematic search until February 2022 identified 41 relevant studies, comprising 29 OSs and 12 RCTs. We
-
Updates in Small Interfering RNA for the Treatment of Dyslipidemias Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2023-10-04 S. Carugo, C. R. Sirtori, G. Gelpi, A. Corsini, L. Tokgozoglu, M. Ruscica
-
Risk Factors for Cardiovascular Disease: Knowledge Gained from the Hispanic Community Health Study/Study of Latinos Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2023-09-29 Amber Pirzada, Jianwen Cai, Christina Cordero, Linda C. Gallo, Carmen R. Isasi, John Kunz, Bharat Thyagaragan, Sylvia Wassertheil-Smoller, Martha L. Daviglus
Purpose of Review The Hispanic Community Health Study/Study of Latinos (HCHS/SOL) has made important contributions on the prevalence of and factors associated with cardiovascular disease (CVD) risk factors among diverse Hispanic/Latino adults in the US. This article summarizes the knowledge gained thus far on major CVD risk factors from this landmark study. Recent Findings HCHS/SOL demonstrated the
-
Atherosclerosis in Systemic Lupus Erythematosus Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2023-09-28 Rachel Tobin, Nidhi Patel, Kardie Tobb, Brittany Weber, Puja K. Mehta, Ijeoma Isiadinso
-
Do Triglyceride-Rich Lipoproteins Equal Low-Density Lipoproteins in Risk of ASCVD? Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2023-09-28 Benjamin N. Wadström, Anders B. Wulff, Kasper M. Pedersen, Børge G. Nordestgaard
-
Impacts of Non-alcoholic Fatty Liver Disease on Acute Coronary Syndrome: Evidence and Controversies Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2023-09-28 Shun-Yi Shi, Fang Jia, Meng-Fei Wang, Ya-Feng Zhou, Jian-Jun Li
-
The TICE Pathway: Mechanisms and Potential Clinical Applications Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2023-09-22 Huimin Xu, Yiyang Xin, Jiaxin Wang, Zixin Liu, Yutong Cao, Weiguo Li, Yun Zhou, Yandong Wang, Peng Liu
-
Fixed Combination for the Treatment of Dyslipidaemia Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2023-09-16 Nicola Ferri, Massimiliano Ruscica, Raul D. Santos, Alberto Corsini
-
Promoting Cardiovascular Health in the Community: Training the Next Generation of Scientists in the Jackson Heart Study Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2023-09-12 Wendy B. White, Amel Mohamed, Kisa Harris, Frances Henderson
-
Precision Nutrition and Cardiovascular Disease Risk Reduction: the Promise of High-Density Lipoproteins Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2023-09-13 Brian V. Hong, Joanne K. Agus, Xinyu Tang, Jack Jingyuan Zheng, Eduardo Z. Romo, Susan Lei, Angela M. Zivkovic
Purpose of Review Emerging evidence supports the promise of precision nutritional approaches for cardiovascular disease (CVD) prevention. Here, we discuss current findings from precision nutrition trials and studies reporting substantial inter-individual variability in responses to diets and dietary components relevant to CVD outcomes. We highlight examples where early precision nutrition research
-
Invasive Coronary Assessment in Myocardial Ischemia with No Obstructive Coronary Arteries Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2023-09-08 Tatsunori Takahashi, Aakriti Gupta, Bruce A. Samuels, Janet Wei
-
Treatment of Lp(a): Is It the Future or Are We Ready Today? Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2023-09-05 Alexandros D. Tselepis
-
The Greatly Under-Represented Role of Smooth Muscle Cells in Atherosclerosis Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2023-09-04 Gordon A. Francis
-
The Intersection Between COVID-19, Cardiovascular Disease, and Diet: a Review Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2023-08-30 Tanusha S. Tholla, Caleigh M. Sawicki, Shilpa N. Bhupathiraju
Purpose of Review Cardiovascular disease (CVD) is one of the top comorbidities associated with COVID-19—both pre- and post-infection. This review examines the relationships between COVID-19 infection and cardiovascular health, with a specific focus on diet as an important modifiable risk factor. Recent Findings Pandemic era studies of individuals battling and recovering from COVID-19 infection suggest
-
Updates in Drug Treatment of Severe Hypertriglyceridemia Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2023-08-29 Ioanna Gouni-Berthold, Jonas Schwarz, Heiner K. Berthold
Purpose of Review To provide an insight into the new pharmacological options for the treatment of severe hypertriglyceridemia (sHTG). Recent Findings sHTG is difficult to treat. The majority of the traditional pharmacological agents available have limited success in both robustly decreasing triglyceride levels and/or in reducing the incidence of acute pancreatitis (AP), the most severe complication
-
Mechanosensing and Mechanosignal Transduction in Atherosclerosis Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2023-08-24 Suneha G. Rahaman, Manisha Mahanty, Pritha Mukherjee, Bidisha Dutta, Shaik O. Rahaman
-
The Pandemic of Coronary Heart Disease in the Middle East and North Africa: What Clinicians Need to Know Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2023-08-24 Yosef Manla, Wael Almahmeed
-
The Pandemic of Coronary Artery Disease in the Sub-Saharan Africa: What Clinicians Need to Know Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2023-08-22 Muhammad N. Shehu, Umar G. Adamu, Dike B. Ojji, Okechukwu S. Ogah, Mahmoud U. Sani
-
Cholesterol Screening in Children: Is a Universal Approach Working? Curr. Atheroscler. Rep. (IF 5.8) Pub Date : 2023-08-18 Tracie K. Lin, Thomas C. Dispenza
Purpose of Review: Ample evidence supports that an individual’s lifetime risk of atherosclerotic cardiovascular disease correlates to long-term, cumulative exposure to circulating cholesterol levels, beginning in childhood. Selective screening strategies based on family history fail to identify many children with hypercholesterolemia. Universal cholesterol screening in childhood is a worthwhile goal